Search results
Results from the WOW.Com Content Network
Alnylam to Webcast R&D Day CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, today announced that it will webcast its upcoming R ...
There, she was vice-president and medical director on the executive team of GSK's UK subsidiary. She then became GSK's Senior Vice President and Chief of Strategy and R&D. She was named in the 2011 Powerlist of Britain's Most Influential Black People. [2] In the 2012 Powerlist she was named at number five. [3]
For premium support please call: 800-290-4726 more ways to reach us
[26] [27] The higher dose allowed once per day dosing, which the company and its marketing partner, Lederle, believed would help it compete against Dyazide, which had $210M in sales in 1983. [26] However, the company's patents on the drug were declared invalid in court, and its marketing exclusivity expired in 1987, prompting a rush of generic ...
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...
For premium support please call: 800-290-4726 more ways to reach us
The R&D and marketing spends address consumer needs while providing value for shareholders, as was seen with Botox. [28] The rejection by Allergan, however, did not prevent Valeant and Pershing from pursuing the Botox maker further. [29] Originally offering $48.30 per share, Valeant increased the cash portion of its offer to $58.30 per share. [30]
Logo of Upjohn Pill & Granule, later The Upjohn Company. The Upjohn Company was an American pharmaceutical manufacturing firm (est. 1886) in Hastings, Michigan, by Dr. William E. Upjohn, a 1875 graduate of the University of Michigan medical school.